Abstract
ABSTRACTThe study aimed to develop chitosan–alginate microcapsule as an oral delivery carrier for IgG. Bovine serum albumin (BSA) was used as the protein to be encapsulated while determining the microcapsule formula by evaluating encapsulation efficiency (EE), loading capacity (LC) and release profile. Results suggested that the optimal formula was composed of 0.1% chitosan, 0.5% CaCl2, 2% sodium alginate and the loading rate of BSA reached 25%. IgG was substituted for BSA and an IgG microcapsule was prepared following the above formula. The EE and LC of the resulted IgG microcapsule reached 76.83% and 18.53%. After 2 h incubation in simulated gastric fluid, the activity of IgG in the microcapsule remained at 79.79% and the total release rate of IgG in a simulated intestinal fluid reached 82.52%. This encapsulation formula was proved to be an effective oral delivery system which would protect the IgG from severe gastric conditions and guarantee an efficient release in the intestinal tract.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
